缬沙坦或替米沙坦联合氨氯地平在高血压治疗中的效果观察

目的:分析探讨缬沙坦或替米沙坦联合氨氯地平在高血压治疗中的疗效及效果观察。方法:选取我院在2015年1月-2016年1月收治的高血压患者150例,随机分为对照组(n=75)和研究组(n=75),对照组患者采用缬沙坦联合氨氯地平治疗高血压。观察对比两组治疗前后心率血压以及不良反应发生率,做好记录。结果:研究组患者的不良反应发生率显著的低于对照组患者(P<0.05),研究组患者治疗前后心率、舒张压和收缩压下降程度显著高于对照组患者(P<0.05)。结论:经本文的研究对比发现,替米沙坦联合氨氯地平治疗高血压的疗效率高于缬沙坦联合氨氯地平,安全性和价值性更高,不良反应发生率低,节约医疗成本,有利于患者康复,值得在临床上推广和应用。

Objective: to investigate the effect and effect of valsartan or timissartan in the treatment of hypertension. Methods:select our hospital in January 2015-January 2016 treated 150 cases of hypertension patients, randomly divided into control group(n = 75) and group(n = 75), the control group were treated by valsartan with amlodipine therapy of hypertension. The blood pressure and the incidence of adverse reactions were observed and compared with the two groups. Results:the incidence of adverse reactions group patients significantly lower than that of control group patients(P < 0.05), the team before and after treatment in patients with heart rate, diastolic and systolic blood pressure drop degree is significantly higher than the control group patients(P < 0.05). Conclusion:compared with in this paper, the research found that telmisartan joint amlodipine treatment the curative effect of hypertension rate is higher than valsartan amlodipine, safety and value higher, lower incidence of adverse reactions, saving medical cost and is helpful for patients rehabilitation, is worth in clinical promotion and application.